Home › Trial NCT05191472
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
- Trial IDNCT05191472
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorAlfred Chung, MD
- Enrollment3
- Start date2022-05-03
- ConditionsMultiple Myeloma · Multiple Myeloma in Relapse · Multiple Myeloma, Refractory · Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Human verification coming soon — the enriched analysis will be viewable here.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.